Brief: Wuxi Biologics Posts FY Revenue Of RMB21,790.0 Million
24/03/2026 10:22
March 24 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK: FY REVENUE RMB 21,790.0 MILLION FY NET INCOME ATTRIBUTABLE RMB 4,908.3 MILLION Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln